Validation of Stability Indicating UPLC Method for Quantification of Lumateperone Impurities and Structural Characterization of Stress Degradation products of Lumateperone by UPLC-MS/MS

In this study a simple analytical approach integrating UPLC and mass spectrometry for resolution, identification and structural characterization of stress degradation products (DPs) of Lumateperone. Lumateperone pure drug was exposed to oxidative, hydrolytic, thermal, and photolytic stresses conditions that produce 7 DPs. The formed DPs along with known nitroso impurities of Lumateperone were resolved on Waters Acquity (100 mm) UPLC® HSS C18 column employing with 15 mM ammonium acetate, methanol and acetonitrile in 45:25:30 (v/v) at pH 4.3 as mobile phase in isocratic mode with 238 nm through UPLC. The method was validated with 10.5–63 µg/mL for Lumateperone and 0.105-0.63 µg/mL for impurities with acceptable recovery and reproducibility. Elucidation of these DPs was achieved by scrutinizing their fragmentation pattern and masses discerned through LC–MS/MS and MSn analysis. These unidentified DPs were ascertained to be (1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5] py-rrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-ol) (DP 1), (1-(4-fluorophenyl) butan-1-one) (DP 2), (1-(4-fluorop-henyl)-4-((3-(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)propyl)(vinyl)amino) butan-1-ol) (DP 3), (2,3,6b,7,8,9, 10,10 a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline) (DP 4), (3-methyl-2,3,6b,7, 10,10a hexah-ydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline) (DP 5), (1-(4-fluoro phenyl)-4-(3-methylpiperidin-1-yl) butan-1-one) (DP 6) and (4-(3-methyl-2,3,6b,7,10, 10a-hexahydro-1H-pyrido [3',4':4,5] pyrrolo[1,2,3de] quino-xalin-8(9H)-yl)-1-phenylbutan-1-one) (DP 7). The proposed analytical method was validated and permissible results were achieved. The results suggest that the method was appropriate for quantifying nitroso impurities of Lumateperone along with structural characterization and quantification of DPs of Lumateperone.

Institutions

Publication Details

Journal
Research Journal of Pharmacy and Technology
Published
2025-08-02
DOI
https://doi.org/10.52711/0974-360x.2025.00531
Primary Topic
3D Surveying and Cultural Heritage
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of Stability Indicating UPLC Method for Quantification of Lumateperone Impurities and Structural Characterization of Stress Degradation products of Lumateperone by UPLC-MS/MS

Research Journal of Pharmacy and Technology
3D Surveying and Cultural Heritage
article

Validation of Stability Indicating UPLC Method for Quantification of Lumateperone Impurities and Structural Characterization of Stress Degradation products of Lumateperone by UPLC-MS/MS

article en

Abstract

In this study a simple analytical approach integrating UPLC and mass spectrometry for resolution, identification and structural characterization of stress degradation products (DPs) of Lumateperone. Lumateperone pure drug was exposed to oxidative, hydrolytic, thermal, and photolytic stresses conditions that produce 7 DPs. The formed DPs along with known nitroso impurities of Lumateperone were resolved on Waters Acquity (100 mm) UPLC® HSS C18 column employing with 15 mM ammonium acetate, methanol and acetonitrile in 45:25:30 (v/v) at pH 4.3 as mobile phase in isocratic mode with 238 nm through UPLC. The method was validated with 10.5–63 µg/mL for Lumateperone and 0.105-0.63 µg/mL for impurities with acceptable recovery and reproducibility. Elucidation of these DPs was achieved by scrutinizing their fragmentation pattern and masses discerned through LC–MS/MS and MSn analysis. These unidentified DPs were ascertained to be (1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5] py-rrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-ol) (DP 1), (1-(4-fluorophenyl) butan-1-one) (DP 2), (1-(4-fluorop-henyl)-4-((3-(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)propyl)(vinyl)amino) butan-1-ol) (DP 3), (2,3,6b,7,8,9, 10,10 a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline) (DP 4), (3-methyl-2,3,6b,7, 10,10a hexah-ydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline) (DP 5), (1-(4-fluoro phenyl)-4-(3-methylpiperidin-1-yl) butan-1-one) (DP 6) and (4-(3-methyl-2,3,6b,7,10, 10a-hexahydro-1H-pyrido [3',4':4,5] pyrrolo[1,2,3de] quino-xalin-8(9H)-yl)-1-phenylbutan-1-one) (DP 7). The proposed analytical method was validated and permissible results were achieved. The results suggest that the method was appropriate for quantifying nitroso impurities of Lumateperone along with structural characterization and quantification of DPs of Lumateperone.

Research Journal of Pharmacy and Technology
Koneru Lakshmaiah Education Foundation (IN)
Openalex Percentile: Top 35%
3D Surveying and Cultural Heritage
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.